+1 (202) 780-3397
A novel intracutaneous microneedle delivery system for the treatment of acute migraine
2nd International Conference and Exhibition on Pharmaceutics and Advanced Drug Delivery Systems
July 05-06, 2019 | Paris, France
Hayley Lewis
Zosano Pharma Corporation, USA
Keynote : Asian J Biomed Pharmaceut Sci
Abstract:
A Novel Intracutaneous Microneedle Delivery System for
zolmitriptan has been developed by Zosano. This delivery
system provides:
• Rapid non oral delivery and pulsatile PK profile
• Room temperature stable formulations
• Patient friendly alternative to injection
• Versatile delivery platform capable of delivering large and
small molecules, and vaccines
In a recent clinical trial zolmitriptan intracutaneous
microneedle delivery system was highly effective for the
treatment of migraine, with statistical significance compared
to placebo achieved for the two co-primary endpoints of pain
freedom at 2 hours and most bothersome symptom absence
at 2 hours. The results in our clinical study show the usefulness
of intracutaneous microneedle delivery system for delivering
zolmitriptan rapidly and yielding pharmacologic effects
quickly which may be a significant advantage compared to
nasal and oral formulations of zolmitriptan. In combination
with our ongoing long-term safety study we believe this
trial will form the basis for approval. In addition, patients
have demonstrated that they are able to reliably apply the
intracutaneous patches and find the product convenient and
easy to use.
Biography:
Hayley Lewis attained her Bachelors in Pharmaceutical Sciences from the University of Greenwich in England, and has attained several management diplomas from Kellogg School of Management, as well as Stanford’s Graduate School of Business. She currently holds the position of Senior Vice President, Operations at Zosano Pharma where she oversees the functional areas of Nonclinical, R&D, Analytical Development and QC, Engineering, Manufacturing, and Regulatory Affairs. Prior to Zosano, she has spent her 26-year career in the field of Drug Delivery at Depomed, Inc, now Assertio Therapeutics, Nektar Therapeutics, Aradigm, GlaxoSmithKline, and Merck-Lipha Pharmaceuticals, involved the areas of Product Development, and Regulatory Affairs and Quality. She has published articles for Drug Development and Delivery, Pharmaceutical Technology, as well as co-authored papers published in Journal of Pharmaceutics and Journal of Pharmaceutical Sciences.
E-mail: hlewis@zosanopharma.com
PDF HTML